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Editorial
Right To Life vs. Upjohn
Mr. W. N. Hubbard, Jr., President of the Upjohn Company, is
quoted as follows in the December, 1972 issue of The Journal of Reproductive Medicine:
"We are confronted with the problem of discrepancy between total
productivity of the human race as it is now organized and its con·
sumptive demands. This discrepancy has led to a threatening differ·
ence between the "have's" and "have·not's." If we are to have each
human life fulfill its potential, then we will have to reduce this dis·
crepancy between productivity and consumptive demand. With limited
resources in an ecology that is subject to harmful alteration, there is
some doubt about the strategy of only increasing production. There·
fore, for the first time, the medical profession is involved in the inhibi·
tion of life and here we look to the most effective and convenient
means. Considering the pathology of population concentration and the
futility of trying to keep up with an explosive birth rate by increasing
productivity alone, the need for limitation of new human life becomes
persuasive."

In order to appreciate fully the insidious significance of the previous
statement, it is important for both physicians and officials of the
pharmaceutical industry to understand what is behind the current
widespread boycott of Upjohn products, which is occurring in Catholic
hospitals all across the United States. The response on the part of the
Upjohn Company officials to resolutions from numerous Boards of
Trustees has betrayed an unfortunate propensity to define improperly
the issues at hand.
First of all, the Catholic medical community fully comprehends the
significance and importance of research in prostaglandins. It is somewhat patronizing to be reminded that prostaglandins do have other
therapeutic potential, even if Prostaglandin F, Alpha is currently approved by the Food and Drug Administration solely for the indication
of intra-amniotic injection to induce abortion in the second trimester.
The therapeutic versatility of prostaglandins is no more relevant to
the issue at hand than would a statement that table salt also has
uses beyond saline amniocentesis.
Likewise, the statement by the Upjohn public relations department
that the company "takes no position" on abortion entirely begs the
question. The promotion of an abortifacient drug is not a "non-
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position" even if the drug is less risky to use than hysterotomy and
salting out. The maternal risks of second trimester abortion are important, but the uniform fetal mortality of second trimester abortions
remains unchanged with intra-amniotic prostaglandin installation and
the deplorable occurrence of previable live births is actually increased.
The only way to eliminate "avoidable risks" to the mother and the
unborn child is to ban this barbaric procedure altogether.
Nevertheless, we cannot insist that every corporate official subscribe
to the tenets of the Right to Life Movement. What we cannot accept,
however, is the fact that the chief corporate officer of a major pharmaceutical company has publicly announced that the company will
divert part of its research and development effort, however large or
small, into finding "the most effective and convenient means" of killing. Mr. Hubbard blandly accepts the propriety of the medical profession's involvement in "the inhibition of life." His viewpoint may not
be unique, but it is certainly the first public statement of its type and,
as such, it must call forth the most vigorous protest from all who deplore the current anti-life trend in our society. Mr. Hubbard borrows
from the Apocalyptic Demographers in suggesting a present population
crisis demanding lethal solutions. His viewpoint would not be supported by anything resembling a scientific consensus, especially in this
country now experiencing the lowest birth rate in its history and a
growth rate less than zero population growth. Putting aside the merits
of Mr. Hubbard's population theories, however, one cannot avoid a
feeling of affront at hearing life-inhibition promoted as a strategy by
a leading spokesman for one of the life sciences. Those of us in the
medical profession have every reason to expect that the pharmaceutical
industry will stand with us in a united front against any encroachment
on the inviolability of human life notwithstanding any alleged societal
benefits to be derived from such an encroachment.
Until such time as the Upjohn Company publicly reasserts its regard
for the sanctity of life at all stages of life's continuum, every physician
is urged to form a right conscience and make an informed judgement
regarding the dispensing of any Upjohn product, either' in his private
practice or his hospital affiliations, particularly whenever a generically
equivalent product is available.
-E. F. D.
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